Australia’s Full Federal Court rules on Myriad patent
In a decision that directly addresses the US Supreme Court’s Myriad decision last year, Australia’s Full Federal Court held that Myriad’s patent for an isolated gene is patentable
The patent at the centre of the dispute (Australian patent 686004, held by Myriad Genetics) covers the isolated BRCA1 gene. Cancer Voices Australia challenged the validity of the patent, arguing that the isolated molecules were not materially different from the...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.